Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMGX0Y8)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
GTVQXKHWYDSDNM-JRHNIRLTSA-N; AC1O44IH; CTK8F0257; AN-16504; (1S,2S)-2-[(2S)-2-amino-3-(2,6-dioxo-3H-purin-9-yl)-1-hydroxy-1-oxopropan-2-yl]cyclopropane-1-carboxylic acid; (1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(2,6-dioxo-3H-purin-9-yl)ethyl]cyclopropanecarboxylic; [3H]alpha-9'-xantheylmethyl-2-(carboxycyclopropyl)glycine; LY341495
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
